CN113797286A - Traditional Chinese medicine formula for treating hypertension, hyperlipidemia, hyperglycemia and hyperuricemia - Google Patents
Traditional Chinese medicine formula for treating hypertension, hyperlipidemia, hyperglycemia and hyperuricemia Download PDFInfo
- Publication number
- CN113797286A CN113797286A CN202010556237.3A CN202010556237A CN113797286A CN 113797286 A CN113797286 A CN 113797286A CN 202010556237 A CN202010556237 A CN 202010556237A CN 113797286 A CN113797286 A CN 113797286A
- Authority
- CN
- China
- Prior art keywords
- parts
- patients
- traditional chinese
- chinese medicine
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 15
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 15
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 14
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 14
- 241001076416 Dendrobium tosaense Species 0.000 claims abstract description 12
- 241000222336 Ganoderma Species 0.000 claims abstract description 12
- 235000006533 astragalus Nutrition 0.000 claims abstract description 12
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 10
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims abstract description 10
- 241000018646 Pinus brutia Species 0.000 claims abstract description 10
- 235000011613 Pinus brutia Nutrition 0.000 claims abstract description 10
- 241000045403 Astragalus propinquus Species 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 14
- 208000024891 symptom Diseases 0.000 abstract description 10
- 208000008589 Obesity Diseases 0.000 abstract description 4
- 235000020824 obesity Nutrition 0.000 abstract description 4
- 206010067484 Adverse reaction Diseases 0.000 abstract description 3
- 241001061264 Astragalus Species 0.000 abstract description 3
- 230000006838 adverse reaction Effects 0.000 abstract description 3
- 230000032683 aging Effects 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000007170 pathology Effects 0.000 abstract description 3
- 210000004233 talus Anatomy 0.000 abstract description 3
- 229940126673 western medicines Drugs 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 2
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 230000036772 blood pressure Effects 0.000 description 9
- 244000269722 Thea sinensis Species 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- 240000008397 Ganoderma lucidum Species 0.000 description 4
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 4
- 230000003750 conditioning effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 229940127088 antihypertensive drug Drugs 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000003860 sleep quality Effects 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000015091 medicinal tea Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a traditional Chinese medicine formula for treating hypertension, hyperlipidemia, hyperglycemia and hyperuricemia, which is prepared from astragalus, dendrobium officinale, lucid ganoderma, American ginseng and pine needles; the operation is simple, the effect on patients with mild symptoms is obvious, and the side effect is small; the traditional Chinese medicine composition can improve the adverse reaction of western medicines on bodies of moderate patients and severe patients, effectively improve and treat the symptoms of the patients and improve the immunity. After the medicine is taken for half a year, people with obesity caused by pathology can achieve the effect of slimming, the formula can be adjusted according to different constitutions of patients, and the medicine is suitable for patients with different constitutions; the formula can also delay aging and prolong life by continuously insisting on taking the formula.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine formulas, in particular to a traditional Chinese medicine formula for treating hypertension, hyperlipidemia, hyperglycemia and hyperuricemia.
Background
At present, most of effective medicaments for treating hypertension, hyperlipidemia, hyperglycemia and hyperuricemia in the market are western medicaments, and no medicament can simultaneously solve the four problems. The long-term taking of the antihypertensive drug can cause the life-threatening side effects of blurred consciousness, coma, body water shortage, blood vessel embrittlement and the like; side effects of insulin: 1. hypoglycemia: diabetic patients treated with insulin are prone to hypoglycemia, especially before meals and at night; 2. weight gain: after insulin is injected, abdominal obesity is often caused, and the elderly with diabetes are common and also suffer from obesity or arteriosclerosis.
Disclosure of Invention
Aiming at the technical defects, the invention aims to provide a traditional Chinese medicine formula for treating hypertension, hyperlipidemia, hyperglycemia and hyperuricemia, which is simple to operate, has obvious effect on patients with mild symptoms and small side effect; adverse reactions of western medicines on bodies can be improved for moderate patients and severe patients, symptoms of the patients can be effectively improved and treated, and immunity is improved; the medicine is relatively long for patients with genetic diseases and single diseases. The weight-reducing effect can be achieved for people who are obese due to pathology after taking the medicine for half a year, the formula can be adjusted according to different constitutions and different symptoms of patients, and the medicine is suitable for patients with different constitutions; the formula can also delay aging and prolong life by continuously taking the food.
In order to solve the technical problems, the invention adopts the following technical scheme:
a traditional Chinese medicine formula for treating hypertension, hyperlipidemia, hyperglycemia and hyperuricemia is prepared from the following raw materials in parts by weight:
5-10 parts of astragalus membranaceus, 5-10 parts of dendrobium officinale, 5-10 parts of lucid ganoderma, 5-10 parts of American ginseng and 5-10 parts of pine needles.
The traditional Chinese medicine formula for treating hypertension, hyperlipidemia, hyperglycemia and hyperuricemia is characterized by being prepared from the following raw materials in parts by weight:
3-7 parts of astragalus membranaceus, 3-7 parts of dendrobium officinale, 3-7 parts of lucid ganoderma, 3-7 parts of American ginseng and 3-6 parts of pine needles.
The formula mainly adopts a plurality of rare Chinese herbal medicines, and the astragalus, the dendrobium officinale and the lucid ganoderma are all common medicinal materials for health preservation and nourishing, so that the condition that the body is in sub-health due to excessive worry and worry is improved.
The astragalus has various effects of tonifying qi, consolidating exterior, promoting urination, strengthening heart, reducing blood pressure, resisting bacteria, expelling pus, promoting granulation and the like, and is one of the traditional Chinese medicinal materials in China.
Dendrobium officinale is recorded in Bencao gang mu, and can help to reduce weight and prolong life, promote the production of body fluid, benefit stomach, moisten lung, tonify kidney, nourish yin, clear heat, improve eyesight, strengthen waist, reduce blood sugar and inhibit tumors.
Ganoderma lucidum is the best immune function regulating and activating agent, and can significantly improve the immune function of the organism, enhance the anticancer ability of patients, protect liver and detoxify the ganoderma lucidum to protect the liver from being damaged by various physicochemical and biological factors. The administration of Ganoderma can protect liver and relieve liver injury before or after liver injury occurs. The ganoderma lucidum can promote the metabolism of the liver to drugs and poisons, and has definite curative effect on toxic hepatitis. Animal experiments and clinical experiments for preventing and treating cardiovascular diseases show that the ganoderma lucidum can effectively expand coronary arteries, increase coronary blood flow, improve myocardial microcirculation, enhance myocardial oxygen and energy supply, prevent and treat hyperlipidemia patients, can obviously reduce blood cholesterol, lipoprotein and triglyceride, and can prevent formation of atherosclerotic plaques.
The invention has the beneficial effects that:
the formula of the invention is simple to operate, has obvious effect on patients with mild symptoms and has small side effect; the traditional Chinese medicine composition can improve the adverse reaction of western medicines on bodies of moderate patients and severe patients, effectively improve and treat the symptoms of the patients and improve the immunity. After the medicine is taken for half a year, people with obesity caused by pathology can achieve the effect of slimming, the formula can be adjusted according to different constitutions of patients, and the medicine is suitable for patients with different constitutions; the formula can also delay aging and prolong life by continuously taking the food.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
A traditional Chinese medicine formula for treating hypertension, hyperlipidemia, hyperglycemia and hyperuricemia is prepared from the following raw materials in parts by weight:
7 parts of astragalus membranaceus, 9 parts of dendrobium officinale, 6 parts of lucid ganoderma, 8 parts of American ginseng and 6 parts of pine needle.
The preparation method comprises the following steps:
drying and crushing astragalus membranaceus, dendrobium officinale, lucid ganoderma, American ginseng and pine needles, respectively storing, and filling into disposable plant fiber tea bags according to the proportion, wherein every 30 g of medicinal powder is packaged by a pure cotton bag to be taken as medicinal tea; 2000-2500 ml of water which must be taken every day as a substitute for tea drink can promote metabolism in vivo and achieve the best curative effect.
Example 2
The traditional Chinese medicine formula for treating hypertension, hyperlipidemia, hyperglycemia and hyperuricemia is characterized by being prepared from the following raw materials in parts by weight:
5 parts of astragalus membranaceus, 7 parts of dendrobium officinale, 5 parts of lucid ganoderma, 6 parts of American ginseng and 5 parts of pine needle.
The preparation method comprises the following steps:
drying and crushing astragalus membranaceus, dendrobium officinale, lucid ganoderma, American ginseng and pine needles, respectively storing, mixing according to a ratio, pressing into tablets, and packaging the tablets into bottles every 5 g/tablet; the medicine is taken in the morning and at night, 3-5 granules are taken each time; can be used for replacing tea when the tea is not convenient to be brewed.
Example 3
The traditional Chinese medicine formula for treating hypertension, hyperlipidemia, hyperglycemia and hyperuricemia is characterized by being prepared from the following raw materials in parts by weight:
7 parts of astragalus membranaceus, 6 parts of dendrobium officinale, 5 parts of lucid ganoderma, 6 parts of American ginseng and 5 parts of pine needle.
The preparation method comprises the following steps:
the formula is suitable for water-soluble extraction, and is prepared into concentrated oral liquid through a component extraction technology, so that the oral liquid is convenient to take; 10ml × 10ml once, 3 times a day.
In order to optimize the extraction process conditions, the extraction research is carried out by adopting an orthogonal experimental method in the experiment.
Clinical cases
Typical case one: tan a certain woman in age of 40 years, height 155, weight 128 jin, suffering from hypertension for 6 years, blood pressure 160/110mmHg, hyperglycemia for 3 years, and blood sugar 8.5 mmol/L; oral symptoms: the medicine for reducing blood pressure and blood sugar is taken all the year round, so people feel palpitation for a long time, have poor sleep quality and hypomnesis, and feel obesity obviously when the people feel 128 jin of weight. After the traditional Chinese medicine tea is taken for 3 months, the blood sugar is controlled to be about 6mmol/L, the blood pressure is 130/96mmHg, and the indexes are stable; after 7 months, the traditional Chinese medicine tea is continuously taken, the blood pressure and the blood sugar are kept within a normal range, the sleep quality is good, the symptom of palpitation is avoided, the body shape is reduced from XL size to L size although the body weight is not reduced, and all indexes are kept within a normal range (the medicine is taken in 3 months in 2018).
Typical case two: yellow certain, male, 65 years old, height 174, weight 146 jin, suffering from hyperglycemia for more than 16 years, hyperlipemia, hyperuricemia are hospitalized for 12 years, the joints of fingers and toes have been swollen and deformed, the pain is hard to endure and the movement is inconvenient, and daily oral administration of hypoglycemic and hypolipidemic drugs is performed, and the weight is 145 jin. After the traditional Chinese medicine tablet is taken for 14 days, the joint pain is obviously relieved, the traditional Chinese medicine tablet takes part in the comprehensive metabolic regulation for 120 days after the discharge procedure is handled, the indexes of blood sugar and blood fat are controlled in a normal range, and the joints have no pain (after three months, the traditional Chinese medicine tablet also needs indirect administration of antihypertensive drugs for auxiliary regulation). After eleven months, the patient returns to visit, the medicine for reducing blood pressure, blood sugar and uric acid is stopped to be taken after half a year of taking the medicine, and all indexes are normal (the medicine is started in 2016).
Typical case three: some Deng, male, 43 years old, 170 height, 140 jin weight, 160/110mmHg blood pressure, 5.96# mmo1/L blood fat (CHO), (LDL-C)4.66# mmo1/L, (DLU)7.6# mmo1/L blood sugar (DLU), 567.7# mmo1/L uric acid, about 5 years symptom, indirect oral decompression drug control blood pressure, clinical oral prescription: the pressure is high when people stay on duty often and stay up night, the people have irregular diet for a long time, smoke and enjoy spicy food, and the people often drink wine, have high blood pressure, low blood pressure, high maximum pressure of 189/126mmHg, high pressure of 153/95mmHg during taking medicine, feel numbness of the head at half part of the body sometimes when hands are numb at night every day, have heartbeat of basically 135 times per minute, have frequent dizziness, poor insomnia quality and are weak all over the body. After the traditional Chinese medicine oral liquid is taken for two months, the traditional Chinese medicine oral liquid needs indirect administration of antihypertensive drugs for auxiliary conditioning, the blood pressure is 132/84mmHg, the blood fat, the blood sugar and the uric acid tend to normal levels after conditioning for 60 days, and the hand numbness phenomenon disappears in the conditioning process, so that the body is relaxed and powerful, and the sleep quality is good. After conditioning, the prescription is returned seven months later, and all indexes are kept normal under the condition of no medicine (the medicine is started in 5 months in 2019).
It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.
Claims (2)
1. The traditional Chinese medicine formula for treating hypertension, hyperlipidemia, hyperglycemia and hyperuricemia is characterized by being prepared from the following raw materials in parts by weight:
5-10 parts of astragalus membranaceus, 5-10 parts of dendrobium officinale, 5-10 parts of lucid ganoderma, 5-10 parts of American ginseng and 5-10 parts of pine needles.
2. The traditional Chinese medicine formula for treating hypertension, hyperlipidemia, hyperglycemia and hyperuricemia is characterized by being prepared from the following raw materials in parts by weight:
3-7 parts of astragalus membranaceus, 3-7 parts of dendrobium officinale, 3-7 parts of lucid ganoderma, 3-7 parts of American ginseng and 3-6 parts of pine needles.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010556237.3A CN113797286A (en) | 2020-06-17 | 2020-06-17 | Traditional Chinese medicine formula for treating hypertension, hyperlipidemia, hyperglycemia and hyperuricemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010556237.3A CN113797286A (en) | 2020-06-17 | 2020-06-17 | Traditional Chinese medicine formula for treating hypertension, hyperlipidemia, hyperglycemia and hyperuricemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113797286A true CN113797286A (en) | 2021-12-17 |
Family
ID=78892762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010556237.3A Pending CN113797286A (en) | 2020-06-17 | 2020-06-17 | Traditional Chinese medicine formula for treating hypertension, hyperlipidemia, hyperglycemia and hyperuricemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113797286A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173728A (en) * | 2014-09-09 | 2014-12-03 | 胡健 | Traditional Chinese medicine capsule for treating hyperglycemia |
| CN108042716A (en) * | 2017-12-28 | 2018-05-18 | 金华寿仙谷药业有限公司 | A kind of traditional Chinese medicine preparation product of auxiliary hyperglycemic |
-
2020
- 2020-06-17 CN CN202010556237.3A patent/CN113797286A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173728A (en) * | 2014-09-09 | 2014-12-03 | 胡健 | Traditional Chinese medicine capsule for treating hyperglycemia |
| CN108042716A (en) * | 2017-12-28 | 2018-05-18 | 金华寿仙谷药业有限公司 | A kind of traditional Chinese medicine preparation product of auxiliary hyperglycemic |
Non-Patent Citations (2)
| Title |
|---|
| 董看看: "《松针改变生活（家庭科普版）》", 30 November 2011, 陕西人民出版社 * |
| 陆平国: "《营养素私人定制教程》", 31 December 2017, 暨南大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041118A (en) | Composition with effects of reducing blood sugar and reducing blood lipid | |
| CN101450095A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN101450101A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN101884723B (en) | Rhizoma anemarrhenae and rhizoma coptidis composition preparation for treating diabetes and preparation method thereof | |
| CN110251591A (en) | A kind of pharmaceutical composition and its preparation method and application that aided blood pressure-lowering is hypoglycemic | |
| CN101433667A (en) | Pharmaceutical composition with function for reducing blood sugar and preparation method thereof | |
| CN113797286A (en) | Traditional Chinese medicine formula for treating hypertension, hyperlipidemia, hyperglycemia and hyperuricemia | |
| CN113476561A (en) | Traditional Chinese medicine formula for treating diabetes | |
| CN101450174A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN111110714B (en) | Chinese medicinal preparation for treating angina pectoris and atherosclerosis diseases and preparation method thereof | |
| CN102940677B (en) | Medicine composition for treating diabetic foot | |
| CN112438397A (en) | Medicated diet for people with hyperglycemia | |
| CN101450096A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN118235857B (en) | Agilawood and moxa composition, preparation method thereof and application of sobering product | |
| CN115554345B (en) | A Chinese medicinal compound preparation for treating gout and hyperuricemia, and its preparation method | |
| CN103494959B (en) | Drug for treating high blood pressure | |
| CN111773315A (en) | Application of sorghum extract in preparation of pharmaceutical composition for treating hypertension | |
| CN101406666B (en) | Chinese medicine for treating coronary heart disease and angina pectoris, and preparation method and use thereof | |
| CN101810782B (en) | Medicament for treating diabetes | |
| CN102940743A (en) | Medicine composition for treating diabetic foot | |
| CN106138757A (en) | A kind of pharmaceutical composition treating type Ⅱdiabetes mellitus and preparation method thereof | |
| CN101953917B (en) | Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN110101802A (en) | A kind of pharmaceutical composition for treating hypertension | |
| CN101036714B (en) | Medicinal composition for treating and/or preventing diabetes | |
| CN102613549A (en) | Diet therapy product capable of regulating blood sugar and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211217 |